Ipsos Healthcare has announced the launch of its syndicated Multiple Sclerosis (MS) Patient Community Panel, part of the Ipsos Healthcare Global Patient Centre of Excellence. The MS Patient Community Panel comprises MS patients across the EU5 and US with a mix of treatment experiences. They will take part in a range of tasks throughout the year (both syndicated and proprietary), moderated by Ipsos Healthcare’s MS experts. This format will enable subscribers to explore key topics throughout the year, whilst also tapping into the community to answer business questions as they arise. Paul O’Meara, Head of Real World Evidence in Autoimmune Diseases at Ipsos Healthcare, commented: “As patients move from recipients to participants, there is an imperative for pharma to put patients at the heart of current and future business models. Designed with this objective in mind, the MS Community will enable our clients to identify unmet patient needs, optimise their patient communications, assess new ideas, and develop personalized medicine strategies for those living with MS.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.